NCT04817800View on ClinicalTrials.gov

To Investigate Drug-drug Interaction and Relative Bioavailability Between the FDC AzelastineHCL/Beclomethasone Dipropionate Nasal Spray, & Beclomethasone Dipropionate Nasal Spray in the Test Vehicle, and RinoClenil® Nasal Spray

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 25, 2021

Primary Completion Date

April 10, 2021

Study Completion Date

April 10, 2021

Conditions

Seasonal Allergic Rhinitis

Interventions

DRUG

140/100 μg Azelastine hydrochloride/Beclomethasone Dipropionate)

It will be nasaly administered

Trial Locations (1)

Unknown

ACDIMA Biocenter, Amman

All Listed Sponsors

lead

Humanis Saglık Anonim Sirketi

INDUSTRY

NCT04817800 - To Investigate Drug-drug Interaction and Relative Bioavailability Between the FDC AzelastineHCL/Beclomethasone Dipropionate Nasal Spray, & Beclomethasone Dipropionate Nasal Spray in the Test Vehicle, and RinoClenil® Nasal Spray | Biotech Hunter | Biotech Hunter